Artal Group S.A. Cyma Bay Therapeutics, Inc. Transaction History

Artal Group S.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$12.63 - $24.47 $3.83 Million - $7.43 Million	303,600 New	303,600 $7.17 Million
Q2 2019 Aug 09, 2019	SELL	$6.05 - $13.66 $3.63 Million - $8.2 Million	-600,000 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$8.16 - $13.42 $816,000 - $1.34 Million	100,000 Added 20.0%	600,000 $7.97 Million
Q4 2018 Feb 11, 2019	SELL	$6.54 - $11.74 $1.96 Million - $3.52 Million	-300,000 Reduced 37.5%	500,000 $3.94 Million
Q2 2018 Aug 10, 2018	BUY	$10.66 - $14.38 $4.26 Million - $5.75 Million	400,000 Added 100.0%	800,000 $10.7 Million
Q1 2018 May 10, 2018	BUY	$9.0 - $15.16 $3.6 Million - $6.06 Million	400,000 New	400,000 $5.2 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.